News und Analysen

New York City-based DSC Meridian Capital initiated a new position in Elme Communities (NYSE:ELME), acquiring 543,081 shares valued at approximately $9.2 million, according to a November 14 SEC

While the pre-holiday season isn't usually a busy time for dividend raises, investors can usually expect a few companies to end the year on a high note by declaring one.

Sure enough, in the fading

New York City-based DSC Meridian Capital fully exited its position in Bausch + Lomb during the third quarter, reducing its holdings by 510,090 shares, a move totaling approximately $6.6 million.

Stock investors have many options to choose among, of course. These include individual equities, exchange-traded funds (ETFs), and mutual funds. But if I had to pick just one stock, I'd invest in

Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60%

Upstart biotech company Viking Therapeutics (NASDAQ: VKTX) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its

Investing in relatively small, unprofitable companies has advantages and drawbacks. On the one hand, these stocks tend to have explosive growth potential, much more so than most of their larger

A volatile trading environment and high inflation should not deter investors from the stock market. These challenges will eventually subside, and equities have performed well over the long term

After trailing broader equities over the past few years, will the healthcare sector finally bounce back in 2026? It's hard to predict those things.

No matter what happens to the industry, though

Several headwinds have pushed Regeneron's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there

Telemedicine leader Teladoc Health (NYSE: TDOC) has been struggling for several years. The company's services are no longer experiencing the kind of demand they did during the pandemic years

Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors should avoid the sector altogether. Many healthcare companies appear to

Looking for great stocks to be had at a bargain? Even though broader equities have performed well this year, there are companies, particularly in sectors that haven't kept up with the rest of the

It now seems so long ago that Pfizer (NYSE: PFE) became the first company in the biopharmaceutical industry to generate over $100 billion in annual sales. The drugmaker achieved this milestone

Even very well-run companies will eventually fall upon hard times. That's the backstory you need to keep in mind when you examine Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). Here's why

Two pieces of encouraging news from Voyager Technologies (NYSE: VOYG) over the last several days have been propelling the company's shares higher. According to data compiled by S&P Global Market

Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine

AbbVie (NYSE: ABBV), a pharmaceutical leader, has faced some challenges over the past three years. The company is managing some patent cliffs and clinical setbacks that worried investors and dinged

This bioproduction tools provider for cell and gene therapy reported a notable insider sale amid a modestly downtrending share price.

Troy Wichterman, Chief Financial Officer of BioLife Solutions (N

Are you looking for a top growth stock to buy heading into 2026? Although valuations are high for many stocks, there are some potential deals still out there right now.

Three stocks that haven't

Voyager Technologies (NYSE: VOYG) took its investors on the kind of voyage they enjoy on Wednesday. The space and defense company's stock took off that day, closing the trading session more than 8%

There's an old saying that a rising tide lifts all ships. Ironically enough, the adage doesn't apply to cruise line stocks. Norwegian Cruise Line (NYSE: NCLH) is once again the worst-performing